Sunday, May 27, 2018
 
 
Company News: Page (1) of 1 - 02/09/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Greenberg Traurig Hosts Boston Healthcare Drinks and Dr. Preston Estep for Discussion on Genomics
 
(February 09, 2018)
Greenberg Traurig Hosts Boston Healthcare Drinks and Dr. Preston Estep for Discussion on Genomics

On Monday, Feb. 12, Greenberg Traurig, LLP's Boston office will sponsor and host the Boston Healthcare Drinks' event, featuring Dr. Preston Estep, Director of Gerontology and Director of Collections for the Personal Genome Project at Harvard University. Dr. Estep will share his insights on how genomics is changing human health and longevity.

Prior to Dr. Estep's talk, Dr. Fang Xie and Wayne H. Elowe, leaders of the firm's Biotechnology and Pharmaceutical Industry Group of the Global Life Sciences & Medical Technology Group, will discuss key IP and corporate issues that pharma and medical device companies should be aware of when doing business in China.

In 2016, Greenberg Traurig sponsored and hosted the launch of Healthcare Drinks' Boston Chapter in the firm's Boston office. Healthcare Drinks provides a platform for all sectors of management in the health care industry to meet, exchange ideas and socialize in a casual yet professional, educational and supportive atmosphere.



About Dr. Preston Estep
Dr. Estep performed his doctoral research at The Harvard Molecular Technology Group laboratory of genomics pioneer George Church. He is a Director of the Harvard Personal Genome Project. He is co-founder and Chief Scientific Officer of Veritas Genetics, a genetic testing company in the Boston area, which was recognized in 2016 and 2017 by MIT Technology Review as one of the world's 50 Smartest Companies.

Dr. Estep has co-founded and/or advised multiple startup companies and nonprofit organizations and is a frequent speaker to professional and public audiences. Dr. Estep is also Chairman and co-founder of the Mind First Foundation, which is dedicated to scientific research of the brain. He is the author of The Mindspan Diet, an examination of the longevity diets and genes throughout the world, which was published in 2016 by Ballantine Books/Random House.

About Greenberg Traurig's Life Sciences & Medical Technology Group
Greenberg Traurig's Life Sciences & Medical Technology Group advises clients ranging from startups to large multinational public companies to leading research institutions. The group's attorneys work closely with clients, providing innovative legal counsel to help them achieve their objectives – from discovery through commercialization and product marketing. As part of the group, the Biotechnology and Pharmaceutical Industry Group focuses on advising clients in the biotechnology and pharmaceutical sectors.

About Greenberg Traurig: Greenberg Traurig, LLP (GT) has more than 2,000 attorneys in 38 offices in the United States, Latin America, Europe, Asia and the Middle East. GT has been recognized for its philanthropic giving, was named the largest firm in the U.S. by Law360 in 2017, and is among the Top 20 on the 2017 Am Law Global 100. Web: http://www.gtlaw.com Twitter: @GT_Law.

Read the full story at http://www.prweb.com/releases/2018/02/prweb15192980.htm.


Page: 1


Related Keywords:
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   IBN - IT Weekly Newsletter ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Bellevue Asset Management AG: Bellevue launches dedicated digital health fund
  • Global Chromatography Reagents Market Analysis, Growth, Trends & Forecast 2018-2023, With The Market Forecasted to Register a CAGR of More Than 7% - ResearchAndMarkets.com
  • Life Science Reagents Market to exceed US$ 67.0 Bn by 2026, Says TMR
  • Study on Poor Oral Hygiene Habits of Aging Population Underlines the Importance of Outstanding Dental Care, says Premier Care Dental Group
  • Blood Gas and Electrolyte Analyzer Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2023

    Cancer
  • Genmab Announces that Janssen Will Stop Studies of Daratumumab in Combination with Anti-PD-(L)1
  • NASP Applauds Bipartisan Legislation Introduced to Reduce Drug Costs and Support Access for Seniors with Life-Threatening Specialized Conditions
  • Celgene Corporation Announces Additional $3 Billion Share Repurchase Authorization and Plans to Execute a $2 Billion Accelerated Share Repurchase Program
  • Moorestown Visiting Nurse Association joins the growing enTouch network in New Jersey
  • Achieve Life Sciences, Inc. Announces Reverse Stock Split
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines